[1. Jarkowski A, Forrest A, Sweeney RP et al. Characterization of vancomycin pharmacokinetics in the adult acute myeloid leukemia population. J Oncol Pharm Pract. 2012;18(1):91-6.10.1177/107815521140210721521799]Search in Google Scholar
[2. Marsot A, Boulamery A, Bruguerolle B et al. Vancomycin: A Review of Population Pharmacokinetic Analyses. Clin Pharmacokinet. 2012;51(1):1-13.10.2165/11596390-000000000-0000022149255]Search in Google Scholar
[3. Adane ED, Herald M, Koura F. Pharmacokinetics of Vancomycin in Extremely Obese Patients with Suspected or Confirmed Staphylococcus aureus Infections. Pharmacotherapy. 2015;35(2):127-39.10.1002/phar.153125644478]Search in Google Scholar
[4. Rodvold KA, Blum RA, Fischer JH et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother. 1988;6:848-52.10.1128/AAC.32.6.8481722943415206]Search in Google Scholar
[5. Darko W, Medicis JJ, Smith A et al. Mississippi Mud No More: Cost-Effectiveness of Pharmacokinetic Dosage Adjustment of Vancomycin to Prevent Nephrotoxicity. Pharmacotherapy. 2003;23(5):643-50.10.1592/phco.23.5.643.3219912741439]Search in Google Scholar
[6. Lodise TP, Patel N, Lomaestro BM et al. Relationship between Initial Vancomycin Concentration-Time Profile and Nephrotoxicity among Hospitalized Patients. Clin Infect Dis. 2009;49(4):507-14.10.1086/60088419586413]Search in Google Scholar
[7. De Hoog M, Mouton JW, Van den Anker JN. New dosing strategies for antibacterial agents in the neonate. Semin Fetal Neonatal Med. 2005;10:185-94.10.1016/j.siny.2004.10.00415701583]Search in Google Scholar
[8. Purwonugroho TA, Chulavatnatol S, Preechagoon Y et al. Population Pharmacokinetics of Vancomycin in Thai Patients. Scientific World Journal. 2012;2012:762649.10.1100/2012/762649332248122547995]Search in Google Scholar
[9. Lin WW, Wu W, Jiao Z et al. Population pharmacokinetics of vancomycin in adult Chinese patients with post-craniotomy meningitis and its application in individualised dosage regimens. Eur J Clin Pharmacol. 2016;72(1):29-37.10.1007/s00228-015-1952-626423622]Search in Google Scholar
[10. Stockmann C, Hersh AL, Roberts JK et al. Predictive Performance of a Vancomycin Population Pharmacokinetic Model in Neonates. Infect Dis Ther. 2015;4(2):187-98.10.1007/s40121-015-0067-9447105625998107]Search in Google Scholar
[11. Hahn A, Frenck RW Jr, Zou Y et al. Validation of a pediatric population pharmacokinetic model for vancomycin. Ther Drug Monit. 2015;37(3):413-6.10.1097/FTD.0000000000000153443190525423413]Search in Google Scholar
[12. Beal SL, Boeckmann AJ, Sheiner LB. NONMEM users guide. Parts I–VIII ICON Development Solutions.]Search in Google Scholar
[13. Jamsen KM, McLeay SC, Barras MA, et al. Reporting a population pharmacokineticpharmacodynamic study: a journal's perspective. Clin Pharmacokinet. 2014;53(2):111-2.10.1007/s40262-013-0114-124327237]Search in Google Scholar
[14. Bakke V, Sporsem H, Von der Lippe E et al. Vancomycin levels are frequently subtherapeutic in critically ill patients: a prospective observational study.Acta Anaesthesiol Scand. 2017;61(6): 627-35.10.1111/aas.12897548505428444760]Search in Google Scholar
[15. Campassi ML, Gonzalez MC, Masevicius FD et al. Augmented renal clearance in critically ill patients: incidence, associated factors and effects on vancomycin treatment. Rev Bras Ter Intensiva. 2014; 26:13-20.10.5935/0103-507X.20140003403188624770684]Search in Google Scholar
[16. Rybak MJ, Lomaestro BM, Rotschafer JC et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2009;49: 325–7.10.1086/60087719569969]Search in Google Scholar
[17. Saugel B, Gramm C, Wagner JY et al. Evaluation of a dosing regimen for continuous vancomycin infusion in critically ill patients: an observational study in intensive care unit patients. J Crit Care. 2014; 29:351-5.10.1016/j.jcrc.2013.12.00724456810]Search in Google Scholar
[18. Hutschala D, Kinstner C, Skhirdladze K et al. Influence of Vancomycin on Renal Function in Critically Ill Patients after Cardiac Surgery: Continuous versus Intermittent Infusion. Anesthesiology. 2009;111(2): 356-65.10.1097/ALN.0b013e3181a9727219602966]Search in Google Scholar
[19. Bamgbola O. Review of vancomycin-induced renal toxicity: an update. Ther Adv Endocrinol Metab. 2016;7(3):136-47.10.1177/2042018816638223489239827293542]Search in Google Scholar
[20. Nakamura T, Hashimoto Y, Kokuryo T et al. Effects of fosfomycin and imipenem/cilastatin on nephrotoxicity and renal excretion of vancomycin in rats. Pharmaceutical research.1998;15(5):734-8.10.1023/A:1011971019868]Search in Google Scholar
[21. Philadelphia, PA: Pfizer; 2012. Zosyn (piperacillin-tazobactam) package insert. https://www.pfizermedicalinformation.com/en-us/zosyn/storage-handling.]Search in Google Scholar
[22. Hammond DA, Smith MN, Li C, et al. Systematic Review and Meta-Analysis of Acute Kidney Injury Associated with Concomitant Vancomycin and Piperacillin/tazobactam. Clin Infect Dis. 2017;64 (5):666-74.]Search in Google Scholar
[23. Blevins AM, Lashinsky JN, McCammon C et al. Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin/Tazobactam, Cefepime, or Merope nem. Antimicrob Agents Chemother. 2019. pii:AAC.02658-18.10.1128/AAC.02658-18649606430782987]Search in Google Scholar
[24. Kim T, Kandiah S, Patel M et al. Risk factors for kidney injury during vancomycin and piperacillin/tazobactam administration, including increased odds of injury with combination therapy. BMC research notes. 2015;8(1):579.10.1186/s13104-015-1518-9460906326476979]Search in Google Scholar
[25. Medellín-Garibay SE, Ortiz-Martín B, Rueda-Naharro A et al. Pharmacokinetics of vancomycin and dosing recommendations for trauma patients. J Antimicrob Chemother. 2016;71(2):471-9.10.1093/jac/dkv37226568565]Search in Google Scholar
[26. Sanchez JL, Dominguez AR, Lane JR et al. Population pharmacokinetics of vancomycin in adult and geriatric patients: Comparison of eleven approaches. Int J Clin Pharmacol Ther. 2010;48: 525–33.10.5414/CPP48525]Search in Google Scholar
[27. Garaud JJ, Regnier B, Ingleber F et al. Vancomycin pharmacokinetics in critically ill patients. J Antimicrob Chemother. 1984;14, Suppl. D, 53-5.10.1093/jac/14.suppl_D.53]Search in Google Scholar
[28. Rotschafer JC, Crossley K, Zaske DE et al. Pharmacokinetics of Vancomycin: Observations in 28 Patients and Dosage Recommendations. Antimicrob Agents Chemother. 1982;22(3):391-4.10.1128/AAC.22.3.3911837547137982]Search in Google Scholar
[29. Al-Kofide H, Zaghloul I, Al-Naim L Pharmacokinetics of vancomycin in adult cancer patients. J Oncol Pharm Pract. 2010;16(4):245-50.10.1177/107815520935584720015925]Search in Google Scholar
[30. Moore JN, Healy JR, Thoma BN et al. A Population Pharmacokinetic Model for Vancomycin in Adult Patients Receiving Extracorporeal Membrane. CPT Pharmacometrics Syst Pharmacol. 2016;5(9): 495-502.10.1002/psp4.12112503642427639260]Search in Google Scholar